32 Years Survival after BNCT for Diffuse Astrocytoma
Kamano S
Published on: 2022-02-15
Abstract
CT on Day of Admission

Preoperative MRI T1Weighted

Keywords
Diffuse Astrocytoma, BNCTHistogy of the 1st Operation
Prolification of neoplastic Astrocytes with abundant nuclear atypia in various-sized round nuclei, but no obvious pleomorphic features.

MRI T1 Weighted before the 2nd Operation?
7 years & 6 months after BNCT.

Histology of the 2nd Operation
Most of the Tumor contained abundant hyaline substance mixed with fibrous connective tissue and scattered calcification. Glioma cells were severely damaged by irradiation with densely condensed small nuclei.

CT CE(+)?A Large Cyst occupied?theTumor Site.?Protein rich with Pleocytosis?No Bacilli detected.

MRI T1 weighted CE (+) 14 years 2 months after BNCT.

MRI T1 weighted CE (+) 17 years 8 months after BNCT.

MRI T1 weighted CE (+) 18 years 11 months after BNCT.
Apparent diffusion coefficient: cyst content 2.83?10?³ mm²/sec ventricular fluid 2.85?10?³ mm²/sec.

MRI T1 weighted CE (+)31 years 7 months after BNCT.


Discussion
Scerrati et al. reported that the extent of surgical excision is important, and they achieved a median survival of 12 years for supratentorial WHO grade 2 gliomas.
Bauman G, et al.: Adult supratentorial low-grade glioma: long-term experience at a single institution. A survival rate of 22% at 20 years has been reported.
Conclusion
Currently, accelerator-based neutron sources have been developed as neutron sources in hospital settings. For treatment of diffuse astrocytoma, BNCT will be one of the choice for treatment. Importantly, complete removal of the tumor is essential if possible. Through surgical, radiological, immunological, pharmaceutical or other means.
